ArticleCurrent medical imaging2025
Identification of PD-L1 Expression in Resectable NSCLC using Interpretable Machine Learning Model Based on Spectral CT
Article in Current medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to explore the value of a machine learning model based on spectral computed tomography (CT) for predicting the programmed death ligand-1 (PD-L1) expression in resectable non-small cell lung cancer (NSCLC).
methodsIn this retrospective study, 131 instances of NSCLC who underwent preoperative spectral CT scanning were enrolled and divided into a training cohort (n = 92) and a test cohort (n = 39). Clinical-imaging features and quantitative parameters of spectral CT were analyzed. Variable selection was performed using univariate and multivariate logistic regression, as well as LASSO regression. We used eight machine learning algorithms to construct a PD-L1 expression predictive model. We utilized sensitivity, specificity, accuracy, calibration curve, the area under the curve (AUC), F1 score and decision curve analysis (DCA) to evaluate the predictive value of the model.
resultsAfter variable selection, cavitation, ground-glass opacity, and CT40keV and CT70keV at venous phase were selected to develop eight machine learning models. In the test cohort, the extreme gradient boosting (XGBoost) model achieved the best diagnostic performance (AUC = 0.887, sensitivity = 0.696, specificity = 0.937, accuracy = 0.795 and F1 score = 0.800). The DCA indicated favorable clinical utility, and the calibration curve demonstrated the model's high level of prediction accuracy. DISCUSSION: Our study indicated that the machine learning model based on spectral CT could effectively evaluate the PD-L1 expression in resectable NSCLC.
conclusionThe XGBoost model, integrating spectral CT quantitative parameters and imaging features, demonstrated considerable potential in predicting PDL1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.